The therapeutic effect of leucogen in treating alcoholic liver cirrhosis with thrombocytopenia or leukopenia
BACKGROUND: Thrombocytopenia and leukopenia are common complications of alcoholic liver cirrhosis (ALC) and are associated with an increased risk of bleeding, infection and mortality. OBJECTIVES: Evaluate the effectiveness and safety of leucogen, a cysteine derivative that increases platelet (PLT) a...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
King Faisal Specialist Hospital and Research Centre
2025-01-01
|
| Series: | Annals of Saudi Medicine |
| Online Access: | http://www.annsaudimed.net/doi/10.5144/0256-4947.2025.9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850038988478349312 |
|---|---|
| author | Min Su Mengwen He Jia-Liang Liu Wu-Cai Yang Jian-Jun Wang Chang Guo Yi-Ming Fu Chun-Yan Wang Shuyao Li Dong Ji Hong-Yan Chen |
| author_facet | Min Su Mengwen He Jia-Liang Liu Wu-Cai Yang Jian-Jun Wang Chang Guo Yi-Ming Fu Chun-Yan Wang Shuyao Li Dong Ji Hong-Yan Chen |
| author_sort | Min Su |
| collection | DOAJ |
| description | BACKGROUND: Thrombocytopenia and leukopenia are common complications of alcoholic liver cirrhosis (ALC) and are associated with an increased risk of bleeding, infection and mortality. OBJECTIVES: Evaluate the effectiveness and safety of leucogen, a cysteine derivative that increases platelet (PLT) and white blood cell (WBC) counts in ALC patients. DESIGN: Retrospective SETTING: Department of hepatology, general hospital PATIENTS AND METHODS: Patients with ALC who had thrombocytopenia and/or leukopenia were enrolled between 2022 and 2023 and were divided into two groups based on their treatment: the leucogen group (20 mg, three times per day) and the non-leucogen group. MAIN OUTCOME MEASURES: The primary endpoint was an increase in PLT or WBC of ≥5% from baseline. SAMPLE SIZE: 413 patients (320 patients in the final analysis) RESULTS: In this retrospective study, 320 patients were analyzed post-propensity score matching: 160 patients each in the leucogen and non-leucogen groups. Following 3 months of treatment, the leucogen group experienced a median increase in PLT levels of 1.0×109/L versus a decrease of 3.0×109/L in the non-leucogen group (P=.003), and a median increase in WBC counts of 0.1×109/L compared to a decrease of 0.1×109/L (P=.006). The changes in ALT, AST, and TBIL levels were not significantly different between groups. A higher proportion of patients in the leucogen group experienced increases in both PLT (46.9% vs. 32.5%, P=.012) and WBC counts (50.0% vs. 36.2%, P=.018), and 28.1% of patients in the leucogen group had increases in both parameters, compared to 15.6% in the non-leucogen group (P=.01). The leucogen group also demonstrated greater increases in PLT (OR 1.833; P=.009) and WBC counts (OR 1.759; P=.013) compared to the non-leucogen group. The safety profile of leucogen was favorable, with no significant adverse events reported. Leucogen was particularly beneficial for patients younger than 60 years and those with lower baseline ALT and AST levels, showing significant improvements in both PLT and WBC counts in these subgroups. CONCLUSIONS: Leucogen effectively increased PLT and WBC counts in patients with ALC, showing a favorable safety profile. LIMITATIONS: Retrospective study |
| format | Article |
| id | doaj-art-c20eadc29aba4ca5b34d9fc8ccd5820d |
| institution | DOAJ |
| issn | 0256-4947 0975-4466 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | King Faisal Specialist Hospital and Research Centre |
| record_format | Article |
| series | Annals of Saudi Medicine |
| spelling | doaj-art-c20eadc29aba4ca5b34d9fc8ccd5820d2025-08-20T02:56:27ZengKing Faisal Specialist Hospital and Research CentreAnnals of Saudi Medicine0256-49470975-44662025-01-0145191710.5144/0256-4947.2025.9The therapeutic effect of leucogen in treating alcoholic liver cirrhosis with thrombocytopenia or leukopeniaMin Su0Mengwen He1Jia-Liang Liu2Wu-Cai Yang3Jian-Jun Wang4Chang Guo5Yi-Ming Fu6Chun-Yan Wang7Shuyao Li8Dong Ji9Hong-Yan Chen10From Senior Department of Hepatology, The Fifth Medical Center of the People's Liberation Army (PLA) General Hospital, Beijing, China;From Peking University 302 Clinical Medical School, Beijing, ChinaFrom Hospital of North China Electric Power University, Beijing, ChinaFrom Senior Department of Hepatology, The Fifth Medical Center of the People's Liberation Army (PLA) General Hospital, Beijing, China;From Senior Department of Hepatology, The Fifth Medical Center of the People's Liberation Army (PLA) General Hospital, Beijing, China;From Senior Department of Hepatology, The Fifth Medical Center of the People's Liberation Army (PLA) General Hospital, Beijing, China;From Senior Department of Hepatology, The Fifth Medical Center of the People's Liberation Army (PLA) General Hospital, Beijing, China;From Senior Department of Hepatology, The Fifth Medical Center of the People's Liberation Army (PLA) General Hospital, Beijing, China;From Senior Department of Hepatology, The Fifth Medical Center of the People's Liberation Army (PLA) General Hospital, Beijing, China;From Senior Department of Hepatology, The Fifth Medical Center of the People's Liberation Army (PLA) General Hospital, Beijing, China;From Hospital of North China Electric Power University, Beijing, ChinaBACKGROUND: Thrombocytopenia and leukopenia are common complications of alcoholic liver cirrhosis (ALC) and are associated with an increased risk of bleeding, infection and mortality. OBJECTIVES: Evaluate the effectiveness and safety of leucogen, a cysteine derivative that increases platelet (PLT) and white blood cell (WBC) counts in ALC patients. DESIGN: Retrospective SETTING: Department of hepatology, general hospital PATIENTS AND METHODS: Patients with ALC who had thrombocytopenia and/or leukopenia were enrolled between 2022 and 2023 and were divided into two groups based on their treatment: the leucogen group (20 mg, three times per day) and the non-leucogen group. MAIN OUTCOME MEASURES: The primary endpoint was an increase in PLT or WBC of ≥5% from baseline. SAMPLE SIZE: 413 patients (320 patients in the final analysis) RESULTS: In this retrospective study, 320 patients were analyzed post-propensity score matching: 160 patients each in the leucogen and non-leucogen groups. Following 3 months of treatment, the leucogen group experienced a median increase in PLT levels of 1.0×109/L versus a decrease of 3.0×109/L in the non-leucogen group (P=.003), and a median increase in WBC counts of 0.1×109/L compared to a decrease of 0.1×109/L (P=.006). The changes in ALT, AST, and TBIL levels were not significantly different between groups. A higher proportion of patients in the leucogen group experienced increases in both PLT (46.9% vs. 32.5%, P=.012) and WBC counts (50.0% vs. 36.2%, P=.018), and 28.1% of patients in the leucogen group had increases in both parameters, compared to 15.6% in the non-leucogen group (P=.01). The leucogen group also demonstrated greater increases in PLT (OR 1.833; P=.009) and WBC counts (OR 1.759; P=.013) compared to the non-leucogen group. The safety profile of leucogen was favorable, with no significant adverse events reported. Leucogen was particularly beneficial for patients younger than 60 years and those with lower baseline ALT and AST levels, showing significant improvements in both PLT and WBC counts in these subgroups. CONCLUSIONS: Leucogen effectively increased PLT and WBC counts in patients with ALC, showing a favorable safety profile. LIMITATIONS: Retrospective studyhttp://www.annsaudimed.net/doi/10.5144/0256-4947.2025.9 |
| spellingShingle | Min Su Mengwen He Jia-Liang Liu Wu-Cai Yang Jian-Jun Wang Chang Guo Yi-Ming Fu Chun-Yan Wang Shuyao Li Dong Ji Hong-Yan Chen The therapeutic effect of leucogen in treating alcoholic liver cirrhosis with thrombocytopenia or leukopenia Annals of Saudi Medicine |
| title | The therapeutic effect of leucogen in treating alcoholic liver cirrhosis with thrombocytopenia or leukopenia |
| title_full | The therapeutic effect of leucogen in treating alcoholic liver cirrhosis with thrombocytopenia or leukopenia |
| title_fullStr | The therapeutic effect of leucogen in treating alcoholic liver cirrhosis with thrombocytopenia or leukopenia |
| title_full_unstemmed | The therapeutic effect of leucogen in treating alcoholic liver cirrhosis with thrombocytopenia or leukopenia |
| title_short | The therapeutic effect of leucogen in treating alcoholic liver cirrhosis with thrombocytopenia or leukopenia |
| title_sort | therapeutic effect of leucogen in treating alcoholic liver cirrhosis with thrombocytopenia or leukopenia |
| url | http://www.annsaudimed.net/doi/10.5144/0256-4947.2025.9 |
| work_keys_str_mv | AT minsu thetherapeuticeffectofleucogenintreatingalcoholiclivercirrhosiswiththrombocytopeniaorleukopenia AT mengwenhe thetherapeuticeffectofleucogenintreatingalcoholiclivercirrhosiswiththrombocytopeniaorleukopenia AT jialiangliu thetherapeuticeffectofleucogenintreatingalcoholiclivercirrhosiswiththrombocytopeniaorleukopenia AT wucaiyang thetherapeuticeffectofleucogenintreatingalcoholiclivercirrhosiswiththrombocytopeniaorleukopenia AT jianjunwang thetherapeuticeffectofleucogenintreatingalcoholiclivercirrhosiswiththrombocytopeniaorleukopenia AT changguo thetherapeuticeffectofleucogenintreatingalcoholiclivercirrhosiswiththrombocytopeniaorleukopenia AT yimingfu thetherapeuticeffectofleucogenintreatingalcoholiclivercirrhosiswiththrombocytopeniaorleukopenia AT chunyanwang thetherapeuticeffectofleucogenintreatingalcoholiclivercirrhosiswiththrombocytopeniaorleukopenia AT shuyaoli thetherapeuticeffectofleucogenintreatingalcoholiclivercirrhosiswiththrombocytopeniaorleukopenia AT dongji thetherapeuticeffectofleucogenintreatingalcoholiclivercirrhosiswiththrombocytopeniaorleukopenia AT hongyanchen thetherapeuticeffectofleucogenintreatingalcoholiclivercirrhosiswiththrombocytopeniaorleukopenia AT minsu therapeuticeffectofleucogenintreatingalcoholiclivercirrhosiswiththrombocytopeniaorleukopenia AT mengwenhe therapeuticeffectofleucogenintreatingalcoholiclivercirrhosiswiththrombocytopeniaorleukopenia AT jialiangliu therapeuticeffectofleucogenintreatingalcoholiclivercirrhosiswiththrombocytopeniaorleukopenia AT wucaiyang therapeuticeffectofleucogenintreatingalcoholiclivercirrhosiswiththrombocytopeniaorleukopenia AT jianjunwang therapeuticeffectofleucogenintreatingalcoholiclivercirrhosiswiththrombocytopeniaorleukopenia AT changguo therapeuticeffectofleucogenintreatingalcoholiclivercirrhosiswiththrombocytopeniaorleukopenia AT yimingfu therapeuticeffectofleucogenintreatingalcoholiclivercirrhosiswiththrombocytopeniaorleukopenia AT chunyanwang therapeuticeffectofleucogenintreatingalcoholiclivercirrhosiswiththrombocytopeniaorleukopenia AT shuyaoli therapeuticeffectofleucogenintreatingalcoholiclivercirrhosiswiththrombocytopeniaorleukopenia AT dongji therapeuticeffectofleucogenintreatingalcoholiclivercirrhosiswiththrombocytopeniaorleukopenia AT hongyanchen therapeuticeffectofleucogenintreatingalcoholiclivercirrhosiswiththrombocytopeniaorleukopenia |